SecSonar.com

VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

VYNE Therapeutics Inc. (VYNE) is a Biotechnology company based in US with a market capitalization of $11.4M. Revenue grew 13.8% year-over-year and free cash flow was negative at -$33.1M. This page tracks VYNE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 13 employees · IPO Jan 25, 2018

Valuation

Valuation & price

$0.67 · as of May 17, 2026 · -54.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.41

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$1.46$0.87$0.29Jul 25Dec 25Jun 26Jul 7, 25$1.29Jul 9, 25$1.44Jul 11, 25$1.42Jul 15, 25$1.29Jul 17, 25$1.20Jul 21, 25$1.21Jul 23, 25$1.45Jul 25, 25$1.46Jul 29, 25$1.44Jul 31, 25$0.37Aug 4, 25$0.37Aug 6, 25$0.36Aug 8, 25$0.36Aug 12, 25$0.35Aug 14, 25$0.35Aug 19, 25$0.33Aug 21, 25$0.32Aug 25, 25$0.33Aug 27, 25$0.33Aug 29, 25$0.32Sep 3, 25$0.32Sep 5, 25$0.30Sep 9, 25$0.29Sep 11, 25$0.32Sep 15, 25$0.31Sep 17, 25$0.30Sep 19, 25$0.30Sep 23, 25$0.33Sep 25, 25$0.32Sep 29, 25$0.33Oct 2, 25$0.32Oct 6, 25$0.36Oct 8, 25$0.43Oct 10, 25$0.37Oct 14, 25$0.39Oct 16, 25$0.36Oct 20, 25$0.38Oct 22, 25$0.35Oct 24, 25$0.37Oct 28, 25$0.35Oct 30, 25$0.37Nov 3, 25$0.35Nov 5, 25$0.34Nov 7, 25$0.35Nov 11, 25$0.36Nov 14, 25$0.37Nov 18, 25$0.38Nov 20, 25$0.35Nov 24, 25$0.36Nov 26, 25$0.38Dec 1, 25$0.37Dec 3, 25$0.37Dec 5, 25$0.37Dec 9, 25$0.38Dec 11, 25$0.41Dec 15, 25$0.36Dec 17, 25$0.60Dec 19, 25$0.59Dec 23, 25$0.57Dec 26, 25$0.59Dec 31, 25$0.58Jan 5, 26$0.56Jan 7, 26$0.56Jan 9, 26$0.57Jan 13, 26$0.57Jan 15, 26$0.57Jan 20, 26$0.57Jan 22, 26$0.58Jan 26, 26$0.58Jan 28, 26$0.56Jan 30, 26$0.57Feb 3, 26$0.57Feb 5, 26$0.56Feb 9, 26$0.56Feb 11, 26$0.56Feb 17, 26$0.59Feb 19, 26$0.60Feb 23, 26$0.60Feb 25, 26$0.59Feb 27, 26$0.60Mar 3, 26$0.59Mar 5, 26$0.58Mar 9, 26$0.59Mar 11, 26$0.60Mar 13, 26$0.59Mar 17, 26$0.61Mar 19, 26$0.62Mar 23, 26$0.61Mar 25, 26$0.62Mar 27, 26$0.59Apr 1, 26$0.61Apr 6, 26$0.60Apr 8, 26$0.61Apr 10, 26$0.61Apr 14, 26$0.62Apr 16, 26$0.62Apr 20, 26$0.63Apr 22, 26$0.65Apr 24, 26$0.65Apr 28, 26$0.64Apr 30, 26$0.64May 4, 26$0.66May 6, 26$0.67May 8, 26$0.66May 12, 26$0.66May 15, 26$0.67May 19, 26$0.68May 21, 26$0.68May 26, 26$0.68May 28, 26$0.69Jun 1, 26$0.68Jun 3, 26$0.66Jun 5, 26$0.66Jun 9, 26$0.67Jun 11, 26$0.66Jun 15, 26$0.62Jun 17, 26$0.63Jun 22, 26$0.65Jun 24, 26$0.65Jun 30, 26$0.65
$0.2952-week range$1.46
Loading valuation history…

Fundamentals

Key fundamentals

$11.4M

Market cap

13.8%

Revenue growth (YoY)

96.0%

Gross margin

-$33.1M

Free cash flow (USD)

-$29M

Net debt

Net cash position

0.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$674.0KFY 2017$4.6MFY 2018$10.6MFY 2019$443.0KFY 2020$21.0MFY 2021$931.0KFY 2022$477.0KFY 2023$424.0KFY 2024$501.0KFY 2025$570.0K
$674K$570K

Free cash flow by year

2016 → 2025

FY 2016$-2.3MFY 2017$-28.3MFY 2018$-52.9MFY 2019$-65.1MFY 2020$-137.2MFY 2021$-56.4MFY 2022$-29.2MFY 2023$-25.3MFY 2024$-34.1MFY 2025$-33.1M
-$2.3M-$33.1M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202596.0%
100.0%96.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: May 15, 2026 (EPS $-0.08)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventReverse Merger AnnouncementMay 21, 2026Filing
  • Quarterly report10-Q FiledMay 15, 2026Filing

Questions

Frequently asked questions

What is VYNE Therapeutics Inc.'s market cap?

VYNE Therapeutics Inc. (VYNE) has a market capitalization of $11.4M.

What is VYNE's P/E ratio?

A meaningful P/E ratio is not available for VYNE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is VYNE's price-to-book (P/B) ratio?

VYNE trades at 0.41 times book value per share.

When did VYNE Therapeutics Inc. last report earnings?

VYNE last reported earnings on May 15, 2026; the next date is not yet scheduled.

Are insiders buying VYNE stock?

SEC Form 4 filings show no open-market insider buys at VYNE Therapeutics Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

AIMD

Ainos, Inc.

$11.4M

KPRX

Kiora Pharmaceuticals, Inc.

$11.9M

OSRH

OSR Holdings, Inc.

$10.8M

LEXX

Lexaria Bioscience Corp.

$12.2M

ICU

SeaStar Medical Holding Corporation

$10.5M

HIND

Vyome Holdings, Inc.

$13M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.